apomorphine has been researched along with exenatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abuirmeileh, A; Biggs, CS; Harkavyi, A; Kingsbury, AE; Lever, R; Whitton, PS | 1 |
1 review(s) available for apomorphine and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for apomorphine and exenatide
| Article | Year |
|---|---|
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Endotoxins; Exenatide; Glucagon-Like Peptide-1 Receptor; Levodopa; Locomotion; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Substantia Nigra; Tyrosine 3-Monooxygenase; Venoms | 2008 |